Cipher Pharmaceuticals Inc
SWB:PHE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Cipher Pharmaceuticals Inc
SWB:PHE
|
CA |
|
H
|
Hermes International SCA
XMUN:HMI
|
FR |
|
F
|
Fair Isaac Corp
F:FRI
|
US |
Cipher Pharmaceuticals Inc
Cipher Pharmaceuticals is a specialty drug company that focuses on dermatology and a small number of other prescription products. It does not run a large research lab or a broad drug factory network. Instead, it buys or licenses medicines that already exist or are close to market, then develops, registers, and sells them in the markets where it thinks they can win a place. The company makes money mainly by selling prescription medicines through pharmacies and healthcare channels, and in some cases by earning royalties or other rights-based income from licensed products. Its main customers are doctors who prescribe the drugs, pharmacies that dispense them, and patients who use them, with hospitals and healthcare distributors also playing a role depending on the product. Cipher’s products are aimed at specific treatment areas, so its business depends more on focused brand building, regulatory approvals, and sales execution than on mass-market consumer demand. What makes Cipher different is its role as a small, focused commercializer of niche pharmaceutical products. It looks for medicines that can be taken through approval and brought to market without the cost and risk of discovering drugs from scratch. That model can be attractive in specialty medicine because a single approved product can serve a clear medical need and build a durable business if it is well supported by physicians and pharmacists.
Cipher Pharmaceuticals is a specialty drug company that focuses on dermatology and a small number of other prescription products. It does not run a large research lab or a broad drug factory network. Instead, it buys or licenses medicines that already exist or are close to market, then develops, registers, and sells them in the markets where it thinks they can win a place.
The company makes money mainly by selling prescription medicines through pharmacies and healthcare channels, and in some cases by earning royalties or other rights-based income from licensed products. Its main customers are doctors who prescribe the drugs, pharmacies that dispense them, and patients who use them, with hospitals and healthcare distributors also playing a role depending on the product. Cipher’s products are aimed at specific treatment areas, so its business depends more on focused brand building, regulatory approvals, and sales execution than on mass-market consumer demand.
What makes Cipher different is its role as a small, focused commercializer of niche pharmaceutical products. It looks for medicines that can be taken through approval and brought to market without the cost and risk of discovering drugs from scratch. That model can be attractive in specialty medicine because a single approved product can serve a clear medical need and build a durable business if it is well supported by physicians and pharmacists.
Revenue: Cipher reported first-quarter net revenue of $12.5 million, up 4% year over year, helped by higher licensing revenue and modest growth in the U.S. Natroba business.
Profitability: Adjusted EBITDA rose 25% to $7.7 million, while gross margin improved to 82% from 76% a year ago, aided by licensing revenue and a cleaner comparison against prior-year inventory adjustments.
Cash Flow: The company generated $4.5 million in cash from operations and fully repaid the remaining $5 million on its revolving credit facility, leaving $6.4 million of cash at March 31.
Natroba Strategy: Management said the new direct-to-consumer launch was still in early setup mode in Q1, with no meaningful volume yet, but expects more marketing and traffic in Q2.
Growth Plans: Cipher remains active on four fronts: investing in Natroba, seeking in-licensing or acquisitions, exploring global out-licensing for Natroba, and evaluating company acquisitions that add scale.
Canada Update: The company expects a final Health Canada decision on Natroba by the end of 2026 after its new drug submission was accepted for review in January.
